UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85
UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85
瑞银维持对Apellis Pharmicals的买入，将目标股价下调至85美元
UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $89 to $85.
瑞银分析师埃利安娜·梅尔维持Apellis Pharmicals（纳斯达克股票代码：APLS）的买入并将目标股价从89美元下调至85美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。